Home / Pharma News

Pharma News

Daiichi Sankyo ends deal with Coherus for etanercept biosimilar in Japan

Daiichi Sankyo announced on 5 July 2017 that it was ending its co-development in Japan with Coherus BioSciences (Coherus) of a biosimilar to Amgen’s arthritis drug Enbrel (etanercept).

German drugmaker Stada to be sold for over US$5 billion

After months of discussions, German generics firm Stada has announced that it will be sold for US$5.63 billion to private equity firms Bain Capital and Cinven.

Japan’s Sawai to acquire US generics business Upsher-Smith

Sawai Pharmaceutical Company Ltd (Sawai) has signed an agreement to purchase the generics section of US firm Upsher-Smith in an attempt to enter the vast American pharmaceuticals market. 

Fresenius Kabi to acquire Akorn and Merck KGaA’s biosimilars business

Fresenius Kabi, the generics unit of German healthcare giant Fresenius, announced on 24 April 2017 that it had made two deals ‘to strengthen and diversify’ its business.

Samsung BioLogics and Aurobindo investing in biosimilars

Both Samsung and Aurobindo see a bright future for biosimilars. Samsung BioLogics, which is the specialized biotechnology arm of Samsung, raised almost US$2 billion in November 2016 via an initial public offering (IPO) that valued the company at US$7.9 billion. This, according to Robert Wessman, Chairman and CEO at Alvogen, ‘underlines the confidence of the market in biosimilar companies’. Especially when considering that Samsung BioLogics only came into existence in 2011 [1].

Merck KGaA to sell off biosimilars business

Germany’s drugmaker Merck KGaA (Merck Group) is to sell its biosimilars division, according to a statement made in its 2016 annual report.

Australians pay too much for prescription drugs

Australians are paying way too much for their prescription drugs, according to a new report released in March 2017 by the Grattan Institute, an independent, non-partisan think tank.

CinnaGen to invest in Turkish pharmaceuticals sector

Turkey’s health minister, Mehmet Muezzinoglu, has announced that the country is planning to produce medicines locally by attracting foreign investors. The strategy aims to reduce healthcare spending in the country and reduce its reliance on imports of medicines from foreign countries.

Intas enters top 20 generics firms through Actavis purchase

Intas Pharmaceuticals (Intas) has completed a deal to acquire Actavis UK and Actavis Ireland (Actavis UK and Ireland) from Teva Pharmaceutical (Teva) for over GBP 600 million.

Baxter expands injectables portfolio with purchase of Claris Injectables

US-based Baxter International Inc (Baxter) has announced its acquisition of India’s Claris Injectables Ltd, which will enhance the company’s position in the global injectables market.

Generics News Research General

more

Biosimilars News Research General

more